Marc Casper Sells 4,608 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Key Points

• CEO Marc Casper sold 4,608 Thermo Fisher shares for approximately $2.7 million at an average price of $586.12 under a pre-arranged Rule 10b5-1 trading plan.
• Thermo Fisher reported quarterly EPS of $6.03, beating estimates by $0.32, while revenue rose 10.5% year over year to $11.99 billion. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $619.41; the company also declared a quarterly dividend of $0.47 per share, yielding about 0.3%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc Casper sold 4,608 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $4.68 during trading on Monday, hitting $598.68. 1,711,604 shares of the company's stock were exchanged, compared to its average volume of 2,319,938. The company has a market cap of $221.36 billion, a PE ratio of 32.20, a P/E/G ratio of 2.42 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The stock's 50 day moving average price is $517.63 and its two-hundred day moving average price is $509.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the firm posted $4.28 EPS. The firm's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price target on the stock. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Finally, HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. High Note Wealth LLC lifted its stake in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares in the last quarter. Birchwood Financial Partners Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Core Wealth Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $30,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source